US 12,077,588 B2
Antibodies targeting PDL1 and methods of use thereof
Tea Gunde, Zurich (CH); Matthias Brock, Aesch (CH); Christian Hess, Zurich (CH); and Alexandre Simonin, Rosenau (FR)
Assigned to Numab Therapeutics AG, Horgen (CH)
Appl. No. 16/753,876
Filed by Numab Therapeutics AG, Wädenswil (CH)
PCT Filed Oct. 9, 2018, PCT No. PCT/EP2018/077511
§ 371(c)(1), (2) Date Apr. 6, 2020,
PCT Pub. No. WO2019/072869, PCT Pub. Date Apr. 18, 2019.
Claims priority of application No. 17195781 (EP), filed on Oct. 10, 2017; application No. 18167094 (EP), filed on Apr. 12, 2018; and application No. 18180816 (EP), filed on Jun. 29, 2018.
Prior Publication US 2020/0283528 A1, Sep. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 28 Claims
OG exemplary drawing
 
1. An isolated antibody having a binding specificity for human PDL1 comprising an HCDR1, HCDR2, HCDR3 sequence of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and an LCDR1, LCDR2 and LCDR3 sequence of SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, respectively.